; or (B) to affect any determination under either such subsection made prior to the date of enactment of this Act. (2) Nothing in the amendments made by this section shall be construed— (A) to limit or narrow the ability of the Secretary of Health and Human Services to share confidential commercial information pursuant to a memorandum of understanding, entered into before, on, or after the date of enactment of this section, between the Food and Drug Administration and another Federal department or agency; or (B) as authorizing the Secretary to disclose any information that is confidential commercial or trade secret information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code. 70535. National Centers of Excellence in Continuous Pharmaceutical Manufacturing (a) In general Section 3016 of the 21st Century Cures Act ( 21 U.S.C. 399h ) is amended to read as follows: 3016. National Centers of Excellence in Continuous Pharmaceutical Manufacturing (a) In general The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs— (1) shall solicit and, beginning not later than one year after the date of enactment of the National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019 , receive requests from institutions of higher education to be designated as a National Center of Excellence in Continuous Pharmaceutical Manufacturing (in this section referred to as a National Center of Excellence ) to support the advancement and development of continuous manufacturing; and (2) shall so designate any institution of higher education that— (A) requests such designation